Current Advances in Vaccine Development for Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV)
<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d1447948e132">Severe fever with thrombocytopenia syndrome (SFTS), caused by the tick-borne severe fever with thrombocytopenia syndrome virus (SFTSV), is a d...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Compuscript Ltd
2025-04-01
|
| Series: | Zoonoses |
| Online Access: | https://www.scienceopen.com/hosted-document?doi=10.15212/ZOONOSES-2025-0005 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d1447948e132">Severe fever with thrombocytopenia syndrome (SFTS), caused by the tick-borne severe
fever with thrombocytopenia syndrome virus (SFTSV), is a disease that is endemic to
East Asia and has mortality rates reaching 30%. Despite its substantial public health
impact, no vaccines or antiviral treatments are currently available. The SFTSV genome
encodes key structural proteins, including glycoproteins (Gn and Gc) and nucleocapsid
protein (NP), which serve as critical vaccine targets. This Commentary reviews the
current status of SFTSV-related vaccine platforms—such as viral vectors, inactivated
viruses, DNA, mRNA, and protein-based approaches—and highlights the immune responses
elicited by these platforms against key antigens, particularly glycoproteins and NP.
Future research directions are additionally proposed to accelerate the development
of effective SFTSV vaccines by leveraging insights from existing studies.
</p> |
|---|---|
| ISSN: | 2737-7466 2737-7474 |